ESSA Pharma Inc. announced that Ari Brettman has been appointed to the board of the directors of the Company pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The company also announced that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments. Dr. Brettman is currently a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014. Dr. Brettman is currently a member of the Board of Directors of Praxis Precision Medicines and Anthos Therapeutics as well as an Observer on the Board of Directors of Talaris Therapeutics.